Logo image of CERS

CERUS CORP (CERS) Stock Fundamental Analysis

NASDAQ:CERS - Nasdaq - US1570851014 - Common Stock - Currency: USD

1.44  -0.03 (-2.04%)

After market: 1.44 0 (0%)

Fundamental Rating

2

CERS gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 188 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of CERS have multiple concerns. While showing a medium growth rate, CERS is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

CERS had negative earnings in the past year.
CERS had a positive operating cash flow in the past year.
In the past 5 years CERS always reported negative net income.
CERS had negative operating cash flow in 4 of the past 5 years.
CERS Yearly Net Income VS EBIT VS OCF VS FCFCERS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M

1.2 Ratios

CERS has a Return On Assets of -9.16%. This is in the better half of the industry: CERS outperforms 62.23% of its industry peers.
CERS has a Return On Equity (-34.14%) which is in line with its industry peers.
Industry RankSector Rank
ROA -9.16%
ROE -34.14%
ROIC N/A
ROA(3y)-16.33%
ROA(5y)-19.79%
ROE(3y)-57.26%
ROE(5y)-58.76%
ROIC(3y)N/A
ROIC(5y)N/A
CERS Yearly ROA, ROE, ROICCERS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

The Gross Margin of CERS (60.60%) is comparable to the rest of the industry.
CERS's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for CERS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 60.6%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.16%
GM growth 5Y-1.44%
CERS Yearly Profit, Operating, Gross MarginsCERS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

3

2. Health

2.1 Basic Checks

CERS does not have a ROIC to compare to the WACC, probably because it is not profitable.
CERS has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, CERS has more shares outstanding
The debt/assets ratio for CERS is higher compared to a year ago.
CERS Yearly Shares OutstandingCERS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
CERS Yearly Total Debt VS Total AssetsCERS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

CERS has an Altman-Z score of -4.83. This is a bad value and indicates that CERS is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -4.83, CERS is not doing good in the industry: 70.74% of the companies in the same industry are doing better.
The Debt to FCF ratio of CERS is 12.67, which is on the high side as it means it would take CERS, 12.67 years of fcf income to pay off all of its debts.
CERS's Debt to FCF ratio of 12.67 is fine compared to the rest of the industry. CERS outperforms 74.47% of its industry peers.
CERS has a Debt/Equity ratio of 1.17. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of CERS (1.17) is worse than 80.85% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.17
Debt/FCF 12.67
Altman-Z -4.83
ROIC/WACCN/A
WACC9.09%
CERS Yearly LT Debt VS Equity VS FCFCERS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 2.32 indicates that CERS has no problem at all paying its short term obligations.
With a Current ratio value of 2.32, CERS perfoms like the industry average, outperforming 42.55% of the companies in the same industry.
CERS has a Quick Ratio of 1.63. This is a normal value and indicates that CERS is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.63, CERS is in line with its industry, outperforming 45.74% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.32
Quick Ratio 1.63
CERS Yearly Current Assets VS Current LiabilitesCERS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 33.33% over the past year.
The Revenue has been growing slightly by 7.86% in the past year.
Measured over the past years, CERS shows a quite strong growth in Revenue. The Revenue has been growing by 16.50% on average per year.
EPS 1Y (TTM)33.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20%
Revenue 1Y (TTM)7.86%
Revenue growth 3Y8.07%
Revenue growth 5Y16.5%
Sales Q2Q%12.7%

3.2 Future

CERS is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 5.24% yearly.
The Revenue is expected to grow by 9.19% on average over the next years. This is quite good.
EPS Next Y-20.55%
EPS Next 2Y16.23%
EPS Next 3Y5.24%
EPS Next 5YN/A
Revenue Next Year24.23%
Revenue Next 2Y16.09%
Revenue Next 3Y9.19%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
CERS Yearly Revenue VS EstimatesCERS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 50M 100M 150M 200M
CERS Yearly EPS VS EstimatesCERS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -0.2 -0.4 -0.6

1

4. Valuation

4.1 Price/Earnings Ratio

CERS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CERS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CERS Price Earnings VS Forward Price EarningsCERS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 -20

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, CERS is valued a bit cheaper than 77.66% of the companies in the same industry.
Industry RankSector Rank
P/FCF 41.05
EV/EBITDA N/A
CERS Per share dataCERS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6 0.8 1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.23%
EPS Next 3Y5.24%

0

5. Dividend

5.1 Amount

No dividends for CERS!.
Industry RankSector Rank
Dividend Yield N/A

CERUS CORP

NASDAQ:CERS (6/10/2025, 8:00:00 PM)

After market: 1.44 0 (0%)

1.44

-0.03 (-2.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-01 2025-05-01/amc
Earnings (Next)07-30 2025-07-30/amc
Inst Owners76.25%
Inst Owner Change2.47%
Ins Owners4.57%
Ins Owner Change20.57%
Market Cap275.27M
Analysts80
Price Target4.76 (230.56%)
Short Float %4.84%
Short Ratio7.34
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.31%
Min EPS beat(2)6.63%
Max EPS beat(2)15.99%
EPS beat(4)4
Avg EPS beat(4)20.93%
Min EPS beat(4)6.63%
Max EPS beat(4)34.64%
EPS beat(8)6
Avg EPS beat(8)22.1%
EPS beat(12)8
Avg EPS beat(12)11.2%
EPS beat(16)12
Avg EPS beat(16)14.16%
Revenue beat(2)1
Avg Revenue beat(2)-7.11%
Min Revenue beat(2)-14.57%
Max Revenue beat(2)0.34%
Revenue beat(4)1
Avg Revenue beat(4)-5.41%
Min Revenue beat(4)-14.57%
Max Revenue beat(4)0.34%
Revenue beat(8)1
Avg Revenue beat(8)-7.22%
Revenue beat(12)4
Avg Revenue beat(12)-4.31%
Revenue beat(16)8
Avg Revenue beat(16)0%
PT rev (1m)7.69%
PT rev (3m)19.66%
EPS NQ rev (1m)8.33%
EPS NQ rev (3m)-26.9%
EPS NY rev (1m)-41.3%
EPS NY rev (3m)-65.96%
Revenue NQ rev (1m)2.09%
Revenue NQ rev (3m)-1.36%
Revenue NY rev (1m)2.01%
Revenue NY rev (3m)12.42%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.33
P/FCF 41.05
P/OCF 32.17
P/B 4.96
P/tB 5.08
EV/EBITDA N/A
EPS(TTM)-0.1
EYN/A
EPS(NY)-0.07
Fwd EYN/A
FCF(TTM)0.04
FCFY2.44%
OCF(TTM)0.04
OCFY3.11%
SpS1.08
BVpS0.29
TBVpS0.28
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -9.16%
ROE -34.14%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 60.6%
FCFM 3.24%
ROA(3y)-16.33%
ROA(5y)-19.79%
ROE(3y)-57.26%
ROE(5y)-58.76%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.16%
GM growth 5Y-1.44%
F-Score4
Asset Turnover1
Health
Industry RankSector Rank
Debt/Equity 1.17
Debt/FCF 12.67
Debt/EBITDA N/A
Cap/Depr 120.84%
Cap/Sales 0.89%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.32
Quick Ratio 1.63
Altman-Z -4.83
F-Score4
WACC9.09%
ROIC/WACCN/A
Cap/Depr(3y)132.31%
Cap/Depr(5y)95.58%
Cap/Sales(3y)1.64%
Cap/Sales(5y)1.38%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)33.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20%
EPS Next Y-20.55%
EPS Next 2Y16.23%
EPS Next 3Y5.24%
EPS Next 5YN/A
Revenue 1Y (TTM)7.86%
Revenue growth 3Y8.07%
Revenue growth 5Y16.5%
Sales Q2Q%12.7%
Revenue Next Year24.23%
Revenue Next 2Y16.09%
Revenue Next 3Y9.19%
Revenue Next 5YN/A
EBIT growth 1Y39.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year170.67%
EBIT Next 3Y60.42%
EBIT Next 5YN/A
FCF growth 1Y141.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y167.58%
OCF growth 3YN/A
OCF growth 5YN/A